Surface Oncology Recognized as one of the “Best Places to Work” by Boston Business Journal
CAMBRIDGE, Mass., June 21, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has been recognized as one of the Best Places to Work in 2018 by the Boston Business Journal.
The award was presented last night during a special event at Boston’s Symphony Hall. Ten members of the Surface team, including Vice President for Human Resources Lisa McGrath, were on hand to accept the award for the small company (50 to 99 employees) category.
“It is an honor to be recognized as one of the Boston Business Journal’s Best Places to Work,” said McGrath. “We dedicated ourselves to becoming a company with not only a clear scientific and patient focus, but also one with a strong sense of community and shared purpose. Our employees have been our foundation since the beginning, and as we grow we will continue to foster a workplace built on collaboration, development and mutual respect.”
The 2018 Boston Business Journal Best Places to Work awards recognized 80 companies in the greater Boston area for their commitment to cultivating positive work environments. Honorees were selected and ranked based on size and survey responses provided by employees. The Boston Business Journal will also feature the honorees in a special section in its June 22 edition.
ABOUT SURFACE ONCOLOGY
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment with lead programs targeting CD47, CD73, CD39 and IL-27. Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. The company has a pipeline of seven novel immunotherapies and a strategic collaboration with Novartis focused on up to three next-generation cancer immunotherapies. For more information, please visit www.surfaceoncology.com.
Media Contact:
Paul Goldsmith, Ten Bridge Communications
Paul@Tenbridgecommunications.com
617-697-3479
Investor Contact:
Jessica Fees
JFees@surfaceoncology.com
617-714-4096
© 2018 GlobeNewswire, Inc. All Rights Reserved.
Aptinyx (Nasdaq: APTX) Reports Positive, Statistically Significant, Top-line Data From Phase 2 Study of NYX-783 in Patients With Post-Traumatic Stress Disorder (PTSD)
